Search
argenx SE
ARGXAdd to Watchlist
925.050USD
+73.330+8.61%
Close 07-23 16:00（ET）Quotes delayed by 15 min
57.85BMarket Cap
38.23P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of argenx SE is 8.59, ranking 95 out of 386 in the Biotechnology & Medical Research industry. The average price target is 925.00, with a high of 1124.00 and a low of 715.00.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
1057.225
Target Price
+20.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
495
Total
6
Median
7
Average
Company name
Ratings
Analysts
argenx SE
ARGX
27
Beigene Ltd
ONC
28
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is argenx SE's expected revenue for the next quarter?
argenx SE's expected revenue is 1.61B.
What is argenx SE's price target?
Analysts forecast that argenx SE's price target is USD 925.00, with the highest forecast at USD 1.12K and the lowest forecast at USD 715.00.
How have argenx SEARGX's recent earnings per share performed?
The market expectation was USD 7.57, while argenx SEARGX's earnings per share (EPS) for the previous quarter was USD 5.90. EPS for the next quarter is expected at USD 7.28.
What is the analyst rating for argenx SE?
Based on the ratings of argenx SE's stock from 27 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.